EVALUATING CLINICAL UTILITY OF A UIP GENOMIC CLASSIFIER IN SUBJECTS WITH AND WITHOUT A HRCT PATTERN OF UIP
Jonathan H. Chung(National Jewish Health), Fernando Martínez, Gerard J. Criner(Temple University Hospital), Kevin R. Flaherty(University of Michigan), Ganesh Raghu(University of Washington), Navdeep Rai, Lars Hagmeyer(Krankenhaus Bethanien), Amy Hajari Case(The Ocean Cleanup), Brandon T. Larsen(Mayo Clinic in Arizona), Kevin M. Brown(National Cancer Institute), Jeffrey L. Myers(University of Michigan), David J. Lederer(Regeneron (United States)), P. Sean Walsh(Veracyte (United States)), Steven D. Nathan(Inova Fairfax Hospital), David Lynch, Thomas V. Colby(Mayo Clinic in Arizona), Lori Lofaro(Veracyte (United States)), Jing Huang(Wuhan National Laboratory for Optoelectronics), Murali Ramaswamy(University of Iowa), Steve D. Groshong(National Jewish Health), Hannah Neville(Veracyte (United States)), Giulia C. Kennedy(Veracyte (United States)), Karel Calero(University of South Florida), Daniel G. Pankratz(Veracyte (United States)), John Davis, Yoonha Choi(Ewha Womans University), Umair Gauhar(University of Louisville), Neil M. Barth(Veracyte (United States)), Mark P. Steele(Vanderbilt University), Sadia Benzaquen(Jefferson Einstein Philadelphia Hospital)
Cited by 0
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k